Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response

Perttu Koskenvesa, Anna Kreutzman, Peter Rohon, Markus Pihlman, Emmi Vakkila, Anu Rasanen, Mirja Vapaatalo, Kari Remes, Tuija Lundan, Henrik Hjorth-Hansen, Jukka Vakkila, Bengt Simonsson, Satu Mustjoki, Kimmo Porkka

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalEuropean Journal of Haematology
Volume92
Issue number5
Pages (from-to)413-420
Number of pages8
ISSN0902-4441
DOIs
Publication statusPublished - May 2014
MoE publication typeA1 Journal article-refereed

Fields of Science

  • chronic myeloid leukemia
  • interferon
  • immune system
  • tyrosine kinase inhibitor
  • therapy discontinuation
  • NATURAL-KILLER-CELLS
  • CHRONIC MYELOGENOUS LEUKEMIA
  • CD8(+) T-CELLS
  • CML PATIENTS
  • MESYLATE DISCONTINUATION
  • INTERFERON-ALPHA
  • NK-CELLS
  • REMISSION
  • THERAPY
  • DASATINIB
  • 3121 Internal medicine

Cite this